Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Kindred Biosciences, Inc. (KIN)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-21 | Mar-31-21 | Jun-30-20 | Mar-31-20 | Dec-31-19 | Sep-30-19 | Jun-30-19 | Mar-31-19 |
| | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q |
| Revenues: |
| Vaxart | 3.0 | 2.3 | | | | | | |
| Dechra | 0.2 | 0.6 | | | | | | |
| Asset Sale | 2.2 | | 38.7 | | | | | |
| Two distributors | | | | | | | 1.0 | |
| Other | | | 0.9 | | | | 0.2 | |
| Total revenues | 3.5 | 2.4 | 39.6 | 0.6 | 1.4 | 1.1 | 1.2 | 0.5 |
| Revenue growth [+] | -91.1% | 297.2% | 3101.2% | 17.1% | 5.7% | 72.5% | | |
| Asset Sale | -94.4% | | | | | | | |
| Product Revenues | | -62.4% | -86.8% | | | | | |
| Cost of goods sold | 0.6 | 0.6 | 0.4 | 3.6 | 0.2 | 0.1 | 0.2 | 0.1 |
| Gross profit | 2.9 | 1.8 | 39.2 | -3.0 | 1.2 | 1.0 | 1.1 | 0.4 |
| Gross margin | 81.9% | 75.4% | 99.1% | -493.2% | 86.7% | 87.4% | 86.3% | 82.1% |
| Selling, general and administrative [+] | 5.9 | 4.7 | 5.1 | 8.9 | 9.6 | 9.4 | 9.1 | 9.9 |
| General and administrative | 5.9 | 4.7 | 5.1 | 8.9 | 37.9 | | 9.1 | 9.9 |
| Other selling, general and administrative | | | | | -28.3 | | | |
| Research and development | 5.6 | 6.3 | 7.4 | 8.9 | 7.1 | 7.3 | 6.7 | 7.2 |
| EBITDA [+] | -7.3 | -8.0 | 27.9 | -19.7 | -14.7 | -15.0 | -14.1 | -16.1 |
| EBITDA growth | -126.3% | -59.5% | -297.4% | 21.9% | -5.6% | 12.6% | 23.9% | 59.6% |
| EBITDA margin | -207.2% | -332.5% | 70.5% | -3260.5% | -1050.7% | -1362.4% | -1143.8% | -3132.0% |
| Depreciation and amortization | 1.2 | 1.2 | 1.2 | 1.1 | 0.8 | 0.7 | 0.6 | 0.5 |
| EBIT [+] | -8.5 | -9.2 | 26.7 | -20.7 | -15.5 | -15.7 | -14.7 | -16.6 |
| EBIT growth | -132.0% | -55.7% | -281.2% | 24.6% | -2.3% | 15.9% | 27.1% | 62.3% |
| EBIT margin | -241.6% | -382.7% | 67.5% | -3435.2% | -1106.2% | -1422.7% | -1191.9% | -3229.1% |
| Non-recurring items | | | 2.3 | 1.7 | | | | |
| Interest income | | | | | 1.4 | 0.4 | | |
| Interest income | | | | | 1.4 | 0.4 | | |
| Other income (expense), net | -0.6 | -0.6 | -0.4 | -0.4 | -1.7 | | 0.4 | 0.6 |
| Pre-tax income | -9.1 | -9.7 | 24.0 | -22.8 | -15.7 | -15.3 | -14.3 | -16.1 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -9.1 | -9.7 | 24.0 | -22.8 | -15.7 | -15.3 | -14.3 | -16.1 |
| Net margin | -258.1% | -406.7% | 60.8% | -3774.6% | -1123.1% | -1385.2% | -1157.5% | -3117.5% |
| |
| Basic EPS [+] | ($0.20) | ($0.24) | $0.61 | ($0.58) | ($0.41) | ($0.39) | ($0.37) | ($0.42) |
| Growth | -132.9% | -59.2% | -266.6% | 36.7% | -18.3% | 1.2% | -6.3% | 19.3% |
| Diluted EPS [+] | ($0.20) | ($0.24) | $0.60 | ($0.58) | ($0.41) | ($0.39) | ($0.37) | ($0.42) |
| Growth | -133.6% | -59.2% | -263.0% | 36.7% | -18.3% | 1.2% | -6.3% | 19.3% |
| |
| Shares outstanding (basic) [+] | 45.3 | 41.1 | 39.2 | 39.2 | 38.7 | 38.9 | 38.9 | 37.8 |
| Growth | 15.4% | 4.9% | 0.9% | 3.7% | 24.7% | 15.9% | 35.9% | 35.0% |
| Shares outstanding (diluted) [+] | 45.3 | 41.1 | 40.1 | 39.2 | 38.7 | 38.9 | 38.9 | 37.8 |
| Growth | 12.9% | 4.9% | 3.1% | 3.7% | 24.7% | 15.9% | 35.9% | 35.0% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|